Association Between Statin Use and New-Onset Diabetes in the US: A Retrospective Analysis Using RWE Data

Anand S, Ganguly R, Rastogi M, Bhagat A, Gupta A, Webster D, Verma V, Roy A, Kukreja I, Nayyar A, Sachdev A, Markan R, Seligman M, Brooks L, Goyal R

Objective


Our objective is to assess the association between statin use and the incidence of new-onset diabetes (NODM) in the United States through a retrospective analysis.

Methodology

- A retrospective cohort study utilizing de-identified Optum[®] Market Clarity data between January 1, 2018, and December 31, 2021.
- Incident hypercholesterolemia (HCL) was identified using ICD-10 codes (E78.0, E78.1, E78.2, E78.4, E78.5, E78.9).
- Inclusion criteria: Patients aged ≥18 years with at least two claims or electronic health records (EHR) for hypercholesterolemia diagnosis at least 30 days apart.
- Exclusion criteria: Patients with pre-existing diabetes, prior use of other lipid-lowering drugs, or pre-existing chronic conditions (CCI > 0) in the baseline period of 12 months from the index date.
- Index date: Second prescription fill date (within 6 months of initial statin prescription).
- Continuous eligibility was observed for 24 months post-index date.
- Patients with the first claim for diabetes in the post-index period were considered new-onset patients.
- Propensity score matching: 1:2 ratio for the cohorts matched on demographics.
 - Cohort 1: Patients who developed diabetes on statins.
 - Cohort 2: Patients who did not develop diabetes on statins.
- Clinical notes were analyzed for pre-existing conditions/symptoms of patients with diabetes on

Results

- A total of 21,571,189 patients were identified with an incident HCL diagnosis.
- The study included 370,151 patients aged at least 18 years. There was no significant difference (p=0.169) between age groups (≤50 years, >50 years) (**Figure 1**) and gender (**Figure 2**) in the incidence of HCL.
- After applying the exclusion criteria, 149,793 patients were eligible for analysis, and only 50,667 (33.8%) patients had at least two statin prescriptions within 6 months.
- Out of 50,667 patients, 7.4% were diagnosed with diabetes during the post-index period, while 92.6% did not develop diabetes. The difference was not statistically significant (p = 0.06).
- The highest number of patients were prescribed atorvastatin (55%), followed by simvastatin (17.2%), rosuvastatin (16.5%), pravastatin (5%), and other statins (6.3%).
- Among statin users, rosuvastatin was associated with the highest percentage of diabetes cases (8.2%), followed by pravastatin (7.6%) and atorvastatin (7.5%). These differences were statistically significant (p ≤ 0.001) (Figure 4).
- The average duration for developing diabetes after initiating statin use was over 300 days, irrespective of the statin type.
- Upon reviewing clinical notes, patients diagnosed with diabetes frequently had multiple mentions of diabetes and its symptoms, followed by weight gain or obesity, sleep deprivation, prediabetes, and hyperglycemia (**Figure 5**).



Conclusions

privatior 219 Disorders,

177

Prediabetes, 99

• Newer statins have a lower incidence of diabetes compared to older statins (rosuvastatin/atorvastatin).

Weight issues,

Diabetic symptoms, 377

- Patients on statins require intensive monitoring of blood sugar levels and clinical symptoms for efficient management of diabetes.
- To better predict the development of diabetes in patients on statins, predictive models using NLP techniques should be developed using claims data.
- Limitation: The impact of lifestyle could not be excluded due to limited information in claims data and clinical notes.

References: Ko, Min Jung, et al. "Time-and dose-dependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: a nationwide observational cohort study." *Journal of the American Heart Association* 8.8 (2019): e011320.

Optum